CA2058785C - Methode pour l'obtention de proteines avec des derives fviii et ou a activite fviii - Google Patents

Methode pour l'obtention de proteines avec des derives fviii et ou a activite fviii

Info

Publication number: CA2058785C
Authority: CA; Canada
Prior art keywords: fviii; cells; hours; activity; temperature
Prior art date: 1992-01-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002058785A

Other languages

English (en)

Other versions

CA2058785A1 (fr

Inventor

Poul B. Rasmussen

Ole Nordfang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novo Nordisk AS

Original Assignee

Novo Nordisk AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-06

Filing date

1992-01-06

Publication date

1999-07-06

1992-01-06 Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS

1992-01-06 Priority to CA002058785A priority Critical patent/CA2058785C/fr

1993-07-07 Publication of CA2058785A1 publication Critical patent/CA2058785A1/fr

1999-07-06 Application granted granted Critical

1999-07-06 Publication of CA2058785C publication Critical patent/CA2058785C/fr

2012-01-06 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000000694 effects Effects 0.000 title claims abstract description 16
238000000034 method Methods 0.000 title claims abstract description 11
108090000623 proteins and genes Proteins 0.000 title claims abstract description 9
102000004169 proteins and genes Human genes 0.000 title claims abstract description 8
238000012258 culturing Methods 0.000 claims abstract description 11
210000004962 mammalian cell Anatomy 0.000 claims abstract description 8
238000000338 in vitro Methods 0.000 claims abstract description 5
210000004027 cell Anatomy 0.000 claims description 27
239000013612 plasmid Substances 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 4
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
239000012634 fragment Substances 0.000 claims 2
102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
102000007474 Multiprotein Complexes Human genes 0.000 claims 1
108010085220 Multiprotein Complexes Proteins 0.000 claims 1
239000003114 blood coagulation factor Substances 0.000 claims 1
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract description 39
102100026735 Coagulation factor VIII Human genes 0.000 abstract description 38
239000002609 medium Substances 0.000 description 15
108010054218 Factor VIII Proteins 0.000 description 10
102000001690 Factor VIII Human genes 0.000 description 10
229960000301 factor viii Drugs 0.000 description 10
210000002966 serum Anatomy 0.000 description 7
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 5
239000012679 serum free medium Substances 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
238000003306 harvesting Methods 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
208000009292 Hemophilia A Diseases 0.000 description 3
241000282693 Cercopithecidae Species 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
101150074155 DHFR gene Proteins 0.000 description 2
102100024746 Dihydrofolate reductase Human genes 0.000 description 2
201000003542 Factor VIII deficiency Diseases 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000002301 combined effect Effects 0.000 description 2
108020001096 dihydrofolate reductase Proteins 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000001890 transfection Methods 0.000 description 2
108010047303 von Willebrand Factor Proteins 0.000 description 2
102100036537 von Willebrand factor Human genes 0.000 description 2
229960001134 von willebrand factor Drugs 0.000 description 2
238000001262 western blot Methods 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241001045988 Neogene Species 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
101100016889 Rattus norvegicus Hes2 gene Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
102000057593 human F8 Human genes 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000013028 medium composition Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
101150091879 neo gene Proteins 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000004904 shortening Methods 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1

Landscapes

Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

CA002058785A 1992-01-06 1992-01-06 Methode pour l'obtention de proteines avec des derives fviii et ou a activite fviii Expired - Lifetime CA2058785C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA002058785A CA2058785C (fr)	1992-01-06	1992-01-06	Methode pour l'obtention de proteines avec des derives fviii et ou a activite fviii

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002058785A CA2058785C (fr)	1992-01-06	1992-01-06	Methode pour l'obtention de proteines avec des derives fviii et ou a activite fviii

Publications (2)

Publication Number	Publication Date
CA2058785A1 CA2058785A1 (fr)	1993-07-07
CA2058785C true CA2058785C (fr)	1999-07-06

Family

ID=4149031

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002058785A Expired - Lifetime CA2058785C (fr)	1992-01-06	1992-01-06	Methode pour l'obtention de proteines avec des derives fviii et ou a activite fviii

Country Status (1)

Country	Link
CA (1)	CA2058785C (fr)

1992
- 1992-01-06 CA CA002058785A patent/CA2058785C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2058785A1 (fr)	1993-07-07

Legal Events

Date	Code	Title	Description
1996-06-25	EEER	Examination request
2012-01-06	MKEX	Expiry
2023-10-24	MKEX	Expiry	Effective date: 20120106

Publication	Publication Date	Title
US6358703B1 (en)	2002-03-19	Expression system for factor VIII
US4868112A (en)	1989-09-19	Novel procoagulant proteins
DE3856505T2 (de)	2002-08-08	Proteine mit Faktor VIII Aktivität, Verfahren zu deren Herstellung unter Verwendung von genetisch modifizierten Zellen und diese enthaltende Zusammensetzungen
US8519111B2 (en)	2013-08-27	Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
EP0500734B1 (fr)	1998-02-11	Complexes de proteines presentant l'activite du facteur viii:c, et leur production
CA2451584A1 (fr)	2004-05-29	Adnc modifie du facteur viii et ses derives
AU2002337901A1 (en)	2003-07-03	Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
EP0480923B1 (fr)	1993-09-29	Procede de production de proteines a activite fviii et/ou a derives fviii
CA2058785C (fr)	1999-07-06	Methode pour l'obtention de proteines avec des derives fviii et ou a activite fviii
US5610033A (en)	1997-03-11	Method of producing proteins with FVIII activity and/or FVIII derivatives
Herlitschka et al.	1998	High expression of a B-domain deleted factor VIII gene in a human hepatic cell line
EP1673391B1 (fr)	2008-12-10	ADNc MODIFIE POUR DES NIVEAUX D'EXPRESSION ELEVES DU FACTEUR VIII ET SES DERIVES
AU632495B2 (en)	1993-01-07	Method of producing proteins with fviii activity and/or fviii derivatives
DK168713B1 (da)	1994-05-24	Fremgangsmåde til fremstilling af proteiner med FVIII (Faktor VIII) aktivitet og/eller FVIII derivater
DE68909617T2 (de)	1994-02-10	Verfahren zur herstellung von proteinen mit fviii aktivität und/oder fviii derivate.
Hayashi et al.	1996	Isolated recombinant domain of von Willebrand factor displaying increased sensitivity to ristocetin
EP1454916A1 (fr)	2004-09-08	ADNc modifié du facteur VIII et dérivés
CA2149212A1 (fr)	1994-05-26	Production accrue de proteines recombinantes a activite facteur viii:c
MXPA01005667A (en)	2002-02-26	Expression system for factor viii
HK1080517B (en)	2009-08-07	Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use